NCT06393751 2025-06-03Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerNational Cancer Institute (NCI)Phase 1/2 Withdrawn